STOCK TITAN

Regeneron’s Marion McCourt sells 566 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Regeneron Pharmaceuticals, Inc. (REGN) — EVP Commercial Marion McCourt reported direct sales of 566 common shares across 13 transactions on November 16, 2026, at reported per-share prices ranging from $952.79 to $971.93. The sales were made under a Rule 10b5-1 plan adopted February 17, 2026. A separate holding entry lists 219 shares indirectly held through a 401(k) plan.

Insider McCourt Marion
Role EVP Commercial
Sold 566 shs ($544K)
Type Security Shares Price Value
Sale Common Stock F1, F2 44 $952.79 $42K
Sale Common Stock F1, F3 59 $954.46 $56K
Sale Common Stock F1 30 $955.51 $29K
Sale Common Stock F1 22 $956.01 $21K
Sale Common Stock F1, F4 44 $958.47 $42K
Sale Common Stock F1, F5 66 $959.46 $63K
Sale Common Stock F1, F6 49 $960.31 $47K
Sale Common Stock F1, F7 59 $961.36 $57K
Sale Common Stock F1, F8 41 $962.44 $39K
Sale Common Stock F1, F9 42 $963.70 $40K
Sale Common Stock F1 21 $964.69 $20K
Sale Common Stock F1, F10 63 $965.62 $61K
Sale Common Stock F1 26 $971.93 $25K
Holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 10,305 shares (Direct); Common Stock — 219 shares (Indirect, By 401(k) Plan)
Footnotes (10)
  1. F1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 17, 2026.
  2. F2. Represents volume-weighted average price of sales of 44 shares of Company stock on November 16, 2026 at prices ranging from $952.64 to $952.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2026 at each separate price.
  3. F3. Represents volume-weighted average price of sales of 59 shares of Company stock on November 16, 2026 at prices ranging from $954.44 to $954.49. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2026 at each separate price.
  4. F4. Represents volume-weighted average price of sales of 44 shares of Company stock on November 16, 2026 at prices ranging from $958.29 to $958.77. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2026 at each separate price.
  5. F5. Represents volume-weighted average price of sales of 66 shares of Company stock on November 16, 2026 at prices ranging from $959.18 to $959.59. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2026 at each separate price.
  6. F6. Represents volume-weighted average price of sales of 49 shares of Company stock on November 16, 2026 at prices ranging from $960.07 to $960.49. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2026 at each separate price.
  7. F7. Represents volume-weighted average price of sales of 59 shares of Company stock on November 16, 2026 at prices ranging from $961.26 to $961.46. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2026 at each separate price.
  8. F8. Represents volume-weighted average price of sales of 41 shares of Company stock on November 16, 2026 at prices ranging from $962.15 to $962.57. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2026 at each separate price.
  9. F9. Represents volume-weighted average price of sales of 42 shares of Company stock on November 16, 2026 at prices ranging from $963.32 to $963.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2026 at each separate price.
  10. F10. Represents volume-weighted average price of sales of 63 shares of Company stock on November 16, 2026 at prices ranging from $965.38 to $965.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2026 at each separate price.
Shares sold 566 shares Direct sales reported on November 16, 2026
Sale transactions 13 Reported on November 16, 2026
Reported sale prices $952.79–$971.93 per share Prices reported for the November 16, 2026 sales
Indirect 401(k) plan holding 219 shares Separate holding entry
Rule 10b5-1(c) regulatory
"plan intended to comply with Rule 10b5-1(c)"
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
volume-weighted average price financial
"Represents volume-weighted average price of sales"
Volume-weighted average price (VWAP) is the average price of a stock over a specific time period where each trade is weighted by the number of shares traded, so larger trades influence the average more than small ones. Investors and traders use VWAP as a reference point to judge whether trades are happening at relatively good or poor prices—like checking the average price paid for an item at a market where bulk purchases count more than single-item buys.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many REGN shares did Marion McCourt sell?

She reported selling 566 shares in 13 transactions on November 16, 2026. The reported per-share prices ranged from $952.79 to $971.93, and the sales were made under a Rule 10b5-1 plan adopted February 17, 2026.

What other REGN shares were listed for Marion McCourt?

A separate entry lists 219 shares held indirectly through a 401(k) plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
McCourt Marion

(Last)(First)(Middle)
777 OLD SAW MILL RIVER ROAD

(Street)
TARRYTOWN NEW YORK 10591

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC. [ REGN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP Commercial
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/16/2026S(1)44D$952.79(2)10,827D
Common Stock11/16/2026S(1)59D$954.46(3)10,768D
Common Stock11/16/2026S(1)30D$955.5110,738D
Common Stock11/16/2026S(1)22D$956.0110,716D
Common Stock11/16/2026S(1)44D$958.47(4)10,672D
Common Stock11/16/2026S(1)66D$959.46(5)10,606D
Common Stock11/16/2026S(1)49D$960.31(6)10,557D
Common Stock11/16/2026S(1)59D$961.36(7)10,498D
Common Stock11/16/2026S(1)41D$962.44(8)10,457D
Common Stock11/16/2026S(1)42D$963.7(9)10,415D
Common Stock11/16/2026S(1)21D$964.6910,394D
Common Stock11/16/2026S(1)63D$965.62(10)10,331D
Common Stock11/16/2026S(1)26D$971.9310,305D
Common Stock219IBy 401(k) Plan
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 17, 2026.
2. Represents volume-weighted average price of sales of 44 shares of Company stock on November 16, 2026 at prices ranging from $952.64 to $952.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2026 at each separate price.
3. Represents volume-weighted average price of sales of 59 shares of Company stock on November 16, 2026 at prices ranging from $954.44 to $954.49. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2026 at each separate price.
4. Represents volume-weighted average price of sales of 44 shares of Company stock on November 16, 2026 at prices ranging from $958.29 to $958.77. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2026 at each separate price.
5. Represents volume-weighted average price of sales of 66 shares of Company stock on November 16, 2026 at prices ranging from $959.18 to $959.59. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2026 at each separate price.
6. Represents volume-weighted average price of sales of 49 shares of Company stock on November 16, 2026 at prices ranging from $960.07 to $960.49. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2026 at each separate price.
7. Represents volume-weighted average price of sales of 59 shares of Company stock on November 16, 2026 at prices ranging from $961.26 to $961.46. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2026 at each separate price.
8. Represents volume-weighted average price of sales of 41 shares of Company stock on November 16, 2026 at prices ranging from $962.15 to $962.57. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2026 at each separate price.
9. Represents volume-weighted average price of sales of 42 shares of Company stock on November 16, 2026 at prices ranging from $963.32 to $963.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2026 at each separate price.
10. Represents volume-weighted average price of sales of 63 shares of Company stock on November 16, 2026 at prices ranging from $965.38 to $965.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2026 at each separate price.
/s/ Marion McCourt11/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading